What is the recommended treatment for a pediatric patient with a history of Wilms tumor (nephroblastoma) presenting with an isolated lung relapse?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Isolated Lung Relapse in Wilms Tumor

For pediatric patients with isolated lung relapse of Wilms tumor, aggressive multimodal therapy combining salvage chemotherapy with surgical metastasectomy (when feasible) and consideration of lung radiation therapy offers the best chance for cure, with long-term survival rates approaching 40-60% in appropriately selected patients. 1, 2

Risk Stratification at Relapse

The prognosis and treatment approach depend critically on several factors that must be assessed immediately:

  • Primary tumor histology is the most important prognostic factor: patients with favorable histology at initial diagnosis have significantly better outcomes (5-year OS 89.2%) compared to high-risk histology (5-year OS 44.4%), with diffuse anaplasia having the worst prognosis (OS 22.2%) 2

  • Initial treatment intensity determines salvage options: patients who received less intensive primary therapy (no doxorubicin or radiation) have more therapeutic options available at relapse 1

  • Time to relapse influences prognosis: later relapses generally respond better to retreatment than early relapses 1

  • Response to salvage chemotherapy is a critical prognostic marker, with non-responding disease associated with significantly worse outcomes 2

Salvage Chemotherapy Regimen

The specific chemotherapy approach should be tailored based on prior treatment:

  • For patients who did not receive doxorubicin initially: incorporate anthracyclines into the salvage regimen as these patients retain sensitivity to this drug class 1

  • For patients previously treated with vincristine/dactinomycin/doxorubicin: consider cyclophosphamide/etoposide-based regimens (Regimen M), which have demonstrated efficacy in the metastatic setting 3

  • High-dose chemotherapy with stem cell rescue should be considered for high-risk relapses, though the optimal role continues to be investigated 1

  • Ifosfamide versus cyclophosphamide: the comparative benefit and toxicity profile between these agents in the relapse setting remains under investigation, though both are active against Wilms tumor 1

Role of Surgical Metastasectomy

Complete surgical resection of lung metastases is a critical component of curative therapy:

  • Pulmonary metastasectomy is indicated when complete remission can be achieved, as this allows avoidance of lung irradiation and its associated late effects 2

  • Complete resection of all visible metastases is essential, as persistence of metastases after local treatment is associated with significantly worse outcomes 2

  • Repeated thoracotomies are often indicated to achieve complete clearance of all pulmonary disease 4

  • Timing of surgery: metastasectomy should be performed after initial response to salvage chemotherapy has been assessed, typically after 2-3 cycles 2

Radiation Therapy Considerations

Lung radiation therapy plays an important role in selected patients:

  • Lung RT should be administered to patients with incomplete response to chemotherapy or those with viable tumor in resected metastases 2, 3

  • Patients who achieve complete radiographic response may avoid lung RT if all disease is surgically resected, though this must be balanced against relapse risk 3

  • For patients who received lung RT during primary treatment: re-irradiation requires careful consideration of cumulative doses and late effects, particularly cardiac toxicity given prior anthracycline exposure 4

Response Assessment and Monitoring

Rigorous imaging surveillance is essential during salvage therapy:

  • Chest CT with thin cuts (approximately 1 cm slice thickness) is required to accurately evaluate pulmonary metastases and response to therapy 5

  • Response evaluation should occur after every 2 cycles of chemotherapy to avoid delaying surgery in non-responding disease 5

  • Radiographic complete response does not equal pathologic complete response: 25-40% of patients with apparent complete radiographic response harbor viable tumor, underscoring the need for surgical resection even with excellent imaging response 5

Critical Pitfalls to Avoid

  • Do not delay surgical intervention in patients with resectable disease showing good response to chemotherapy, as complete resection is essential for cure 2

  • Do not rely solely on imaging to determine treatment completion; histologic confirmation of response through surgical resection is critical 5

  • Do not use standard chest imaging protocols: ensure thin-cut chest CT is performed, as small pulmonary nodules may be missed with thicker slices 5

  • Do not underestimate the importance of tumor biology: patients with anaplastic histology, rhabdoid tumor of the kidney (RTK), or clear cell sarcoma of the kidney (CCSK) require more aggressive approaches and have poorer outcomes 1

Special Considerations for Genetic Predisposition

For patients with identified genetic predisposition syndromes (WT1, Beckwith-Wiedemann, DICER1, TRIM28):

  • Continue surveillance of the contralateral kidney with renal ultrasound every 3 months, as these patients remain at risk for second primary tumors 4, 6, 5

  • Genetic counseling and cascade testing of family members should be pursued if not already completed 4

  • Surveillance should continue until at least age 8 years for most predisposition syndromes 4, 6

Expected Outcomes

With appropriate multimodal therapy:

  • Overall 5-year survival for isolated lung relapse ranges from 40-60% in more recently treated patients, representing substantial improvement from historical 30% survival rates 7, 1

  • Patients with favorable histology and complete response to salvage therapy have the best outcomes, with some series reporting survival exceeding 70% 2

  • Patients with high-risk features (anaplastic histology, incomplete response, early relapse) have significantly worse prognosis and may benefit from investigational approaches 1, 2

References

Research

The management of relapsed Wilms tumor.

Hematology/oncology clinics of North America, 1995

Research

Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Repeat Imaging Timing for Metastatic Wilms Tumor on SIOP Preoperative Chemotherapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Genetic Considerations in Wilms Tumor Staging and Surveillance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Wilms' tumor: past, present and (possibly) future.

Expert review of anticancer therapy, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.